{
    "nct_id": "NCT05678205",
    "official_title": "A Multicenter, Open-label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors",
    "inclusion_criteria": "* ECOG performance status 0 to 1.\n* Histologically confirmed HER2 expressed breast or gastric/GEJ cancer IHC ≥ 2+ within 6 months prior to study entry.\n* Confirmed diagnosis of an advanced/unresectable or metastatic HER2+ breast or gastric/GEJ cancer that is refractory to, or intolerable of standard treatment, or for which no standard treatment is available.\n* Must have received prior cancer therapy: Subjects with breast cancer must have received ≥ 2 prior systemic therapies; subjects with gastric/GEJ cancer must have received ≥ 1 prior systemic therapy(ies); subjects with IHC 3+ or IHC 2+/ISH+ cancers must have received previous treatment with a HER2-targeting therapy.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
    "exclusion_criteria": "* Known past or current malignancy other than inclusion diagnosis.\n* Known clinically significant cardiac disease.\n* Active central nervous system (CNS) metastases, or involvement of the CNS, unless there is a history of at least 3 months of sustained remission.\n* Unresolved toxicities from prior anticancer therapy.\n* Ongoing uncontrolled systemic infections requiring antibiotic, anti-fungal, or anti-viral therapy.\n* History of sensitivity or intolerance to cyclophosphamide or fludarabine.\n* Pregnant or lactating females and subjects of both sexes who are not willing to practice birth control from the time of consent through 6 months after administration of the last AB-201 dose.\n* Severe disease progression or health deterioration within 2 weeks prior to lymphodepletion regimen.",
    "miscellaneous_criteria": ""
}